LONG-ACTING APRETUDE WAS PROVEN SUPERIOR AT REDUCING THE RISK OF GETTING HIV VS ONCE-DAILY TRUVADA

Randomized, double-blind, controlled clinical trials were used to make the results of the study less likely to be biased.

In these clinical trials, participants were randomly assigned to receive either APRETUDE + TRUVADA placebo or TRUVADA + APRETUDE placebo. Neither participants nor investigators knew which medicine participants were receiving.

More people stayed HIV negative on APRETUDE than on TRUVADA during the studies.

STUDY 1:

4,566 HIV–NEGATIVE CISGENDER MEN, TRANSGENDER WOMEN, AND PEOPLE AT RISK OF GETTING HIV.
  • On APRETUDE: 12 out of 2,278 people became HIV-1 positive
  • On TRUVADA: 39 out of 2,281 people became HIV-1 positive

Significantly more people stayed HIV-1 negative on APRETUDE vs TRUVADA during the study

After this portion of the study, participants were surveyed

Of those who responded, 96% of participants chose APRETUDE over daily oral TRUVADA as their PrEP option.

When the trial was complete, participants were offered the choice of continuing the study with APRETUDE or TRUVADA. Of the 1,698 participants originally included from the US, 803 (47%) had choice data available. Individuals preferring an oral PrEP option may have chosen not to enroll in the study.

IN STUDY 1

STUDY 2:

3,224 HIV–NEGATIVE CISGENDER WOMEN AT RISK OF GETTING HIV.
  • On APRETUDE: 3 out of 1,613 people became HIV-1 positive
  • On TRUVADA: 36 out of 1,610 people became HIV-1 positive

Significantly more women stayed HIV-1 negative on APRETUDE vs TRUVADA during the study

After this portion of the study, participants were surveyed

Of those who responded, 78% of participants chose APRETUDE over daily oral TRUVADA as their PrEP option.

When the trial was complete, participants were offered the choice of continuing the study with APRETUDE or TRUVADA. Of the 3,028 patients in the study, 2,472 (81%) had choice data available. Individuals preferring an oral PrEP option may have chosen not to enroll in the study.

IN STUDY 2

APRETUDE is given every other month by a healthcare provider after initiation injections have been given 1 month apart for 2 consecutive months. Stay under a provider’s care while receiving APRETUDE. You must receive it as scheduled. If you will miss a scheduled injection by more than 7 days, call your provider right away.

ELIGIBLE PATIENTS MAY PAY AS LITTLE AS A $0 COPAY PER INJECTION ON PRESCRIBED APRETUDE.*

*The APRETUDE Savings Program is subject to eligibility and program terms and conditions and is not health insurance.

GET THE DETAILS

PMUS-CBTWCNT240125